Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (RI-CYCLO)
A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy
Sponsor: Azienda Ospedaliera Brotzu
A PHASE3 clinical study on Glomerulonephritis, Membranous, this trial is ongoing. The trial is conducted by Azienda Ospedaliera Brotzu and has accumulated 8 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Oct 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE3
-
May 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
▶ Show 3 earlier versions
-
Jun 2019 — May 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Jun 2019 [monthly]
Recruiting PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE3
First recorded
Jan 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Azienda Ospedaliera Brotzu
- Azienda Ospedaliera Universitaria Policlinico
- Azienda Sanitaria Locale Roma E
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
- Fondazione Salvatore Maugeri
- Humanitas Hospital, Italy
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Istituto Giannina Gaslini
- Regione Piemonte
- Universita di Verona
- University of Alberta
- University of Bari
- University of Bern
- University of Bologna
- University of Chieti
- University of Messina
- University of Milan
- University of Milano Bicocca
- University of Modena and Reggio Emilia
- University of Pisa
For direct contact, visit the study record on ClinicalTrials.gov .